Adoptive immunotherapy with interleukin-7
AssigneeImmunex Corporation
InventorDavid H. Lynch
Life of this patent
Estimating the term…
Abstract
There is disclosed an immunotherapy method for treating an individual with cancer or a viral infection comprising obtaining lymphoid cells previously exposed to a specific antigen, culturing the lymphoid cells ex vivo in a culture medium containing an effective amount of an IL-7 polypeptide or a functional derivative thereof to induce CTL activity in the lymphoid cells and administering the lymphoid cells having CTL activity for cells displaying the specific antigen to an individual.
Claims31
An immunotherapy method for treating an individual with cancer that responds to immunotherapy and which is formed by specific tumor cells displaying a specific antigen, comprising:
- obtaining lymphoid cells exposed to the specific antigen;
- culturing the lymphoid cells ex vivo in a culture medium comprising an amount of an IL-7 polypeptide sufficient to induce CTL activity in the lymphoid cells;
- and
- administering the lymphoid cells displaying CTL activity to the individual.
A population of activated lymphoid cells for immunotherapy of cancer, comprising a culture of lymphoid cells surviving at least 10 days in ex vivo culture in the presence of at least 2 ng/ml of an IL-7 polypeptide;
- wherein the lymphoid cells display CTL activity characterized by CD8 positive T cells.
A population of activated lymphoid cells for adoptive immunotherapy of cancer formed by specific tumor cells displaying a specific antigen, produced by the process comprising:
- obtaining lymphoid cells exposed to the specific antigen:
- culturing the lymphoid cells ex vivo in a culture medium comprising an amount of an IL-7 polypeptide sufficient to induce CTL activity in the lymphoid cells.
A population of syngeneic lymphoid cells for adoptive immunotherapy of cancer formed from specific tumor cells produced by the process comprising:
- obtaining syngeneic peripheral lymphoid cells;
- and
- culturing the lymphoid cells ex vivo in a culture medium comprising an amount of conspecific IL-7 polypeptide sufficient to induce CTL activity in the lymphoid cells plus up to about 3 ng/ml of an IL-2 polypeptide or derivative thereof.
A method for forming a proliferated population of mammalian cytolytic T lymphocytes having lytic specificity for cells displaying a specific antigen, comprising contacting a T cell population previously exposed to the specific antigen with a culture medium comprising a biologically effective amount of an IL-7 polypeptide.
An isolated population of activated mammalian cytolytic T lymphocytes having lytic specificity for cells displaying a specific antigen wherein the population of proliferated cytotoxic T lymphocytes is produced by an ex vivo process, comprising obtaining a lymphoid cell population exposed to the specific antigen, and contacting the lymphoid cell population with a culture medium comprising a biologically effective amount of an IL-7 polypeptide.
Dependencies are inferred from the claim text.